Drugs for Gram-Negative Bugs from 2010 - 2019: A Decade in Review

Benjamin Pontefract, Pharm.D., BCPS¹, Hong T. Ho¹, Alexandria Crain¹, Madan K. Kharel, Ph.D.², and S. Eric Nybo, Ph.D.¹,†.

¹ Ferris State University, College of Pharmacy, 220 Ferris Drive, Big Rapids, MI, 49307, USA.

² University of Maryland Eastern Shore, Department of Pharmaceutical Sciences, Somerset Hall 214, Princess Anne, MD, 21853, USA.

† Corresponding author. Email inquiries to EricNybo@Ferris.edu.
ABSTRACT

A literature review spanning January 1, 2010, to December 31, 2019, was conducted in PubMed and ISI Web of Science databases to determine the breadth of publication activity in the area of gram-negative bacteria antimicrobial therapy. The number of articles was used as a reflection of scholarly activity. First, PubMed was searched using the following Medical Subject Headings (MeSH): anti-bacterial agents, *Enterobacteriaceae*, *Acinetobacter*, and *Pseudomonas*. A total of 12,643 articles were identified within PubMed, and 77,862 articles were identified within ISI Web of Science including these terms. Second, these articles were categorized by antibiotic class to identify relative contributions to the literature by drug category. Third, these studies were used to identify key trends in the treatment of gram-negative bacterial infections from the past decade. This review highlights advances made in the past ten years in antibacterial pharmacotherapy and some of the challenges that await the next decade of practice.

KEYWORDS: gram-negative bacteria, *Acinetobacter*, *Pseudomonas*, *Enterobacteriaceae*, antibacterial pharmacotherapy
INTRODUCTION

Gram-negative bacteria, specifically gram-negative rods (GNRs), are ubiquitous microorganisms that commonly feature a lipopolysaccharide-adorned outer membrane, a narrow peptidoglycan layer, and an inner membrane which effectively serve as permeability barriers to exogenous chemicals, including antibiotics [1]. GNRs acquire a variety of resistance traits via horizontal gene transfer, including drug efflux permeases, antibiotic-modifying enzymes, bypass targets, and ribosome modification or mutation [1,2]. While genes encoding drug efflux permeases and antibiotic-modifying enzymes (e.g. beta-lactamases) are often acquired through horizontal gene transfer, mutational events are known to produce new phenotypes with modified antibiotic targets (e.g. ribosomal mutation) resulting in diminished antibiotic-target interactions [3,4]. In particular, beta-lactamases play a critical role in catalyzing resistance against beta-lactam antibiotics. Through repeated exposure, GNRs have developed extended-spectrum beta-lactamases (ESBLs), which can confer resistance to penicillins and cephalosporins, and carbapenemases, which can confer resistance to carbapenems [5].

Gram-negative bacteria are responsible for a multitude of infections, including bacteremia, device-associated infections, intraabdominal infections (IAI), urinary tract infection (UTI), community-acquired bacterial pneumonia (CABP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) [1]. Within these disease categories, GNRs compose a significant disease burden, causing upwards of 30% of hospital-acquired infections [6]. Multi-drug resistant (MDR) GNRs, including *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and ESBL producing *Enterobacteriaceae* worldwide are associated with poor patient prognosis.
The exponential growth of such MDR pathogens during the past decades demands a renewed interest in drug discovery and drug development in the search for antibiotics with novel mechanisms. For example, the emergence of multidrug-resistant GNRs educed the repurposing of polymyxins and fosfomycin as antibiotics of "last resort" in the mid-2000s [8,9]. Furthermore, the disease burden of MDR pathogens has precipitated advances in practice development and scholarly activity during the last decade.

The Generating Antibiotics Incentives Now (GAIN) Act was signed into law on July 9, 2012 as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) [7]. The purpose of the GAIN Act was to bolster drug development efforts for the treatment of microorganisms that were growing resistant to antimicrobials in the current formulary. The GAIN Act established the designation of certain new anti-infective agents as qualified infectious disease products (QIDPs) if they treated serious or life-threatening infections caused by emerging infectious disease pathogens or specific MDR pathogens identified by the FDA. In the past decade, 12 new antibiotics have been approved using the QIDP designation (Appendix A).

Eleven of the drugs that were approved using the QIDP designation were approved after the publication of the GAIN Act. These agents have been approved for a variety of infections including complicated urinary tract infections (cUTI), CABP, HAP, VAP, acute bacterial skin and soft tissue infection (ABSSSI), traveler's diarrhea, and complicated intraabdominal infections (cIAI). Under the GAIN Act, new antimicrobials have been approved in virtually every drug class used for the treatment of gram-negative bacterial infections. Three of these agents are of the cephalosporin class or are novel cephalosporin/beta-lactamase inhibitors, including

---

1 The family Enterobacteriaceae is a member of the reclassified phylogenetic order Enterobacterales [99].
ceftolozane/tazobactam, ceftazidime/avibactam, and cefiderocol. The others include carbapenem/beta-lactamase inhibitors meropenem/vaborbactam and imipenem/cilastatin/relebactam, a new fluoroquinolone delafloxacin, tetracycline-family antibiotics eravacycline (a fluorocycline) and omadacycline (a aminomethylcycline), and a new aminoglycoside, plazomicin. Therefore, we conducted a literature review of publications and citations concerning the broad subject of antimicrobial pharmacotherapy of gram-negative bacteria. Using the identified publications, several topics were investigated: 1) trends in scholarship concerning treatment of infections caused by gram-negative bacteria; 2) popularity of drug classes by scholarly interest; 3) novel challenges, opportunities, and themes within prescribing practices; 4) how new drugs approved under the GAIN act are used in clinical practice.

RESULTS and DISCUSSION

Literature review of gram-negative antimicrobial pharmacotherapy

First, search criteria were established for PubMed and ISI Web of Science to locate publications and citations about the use of gram-negative antimicrobials. Search criteria for PubMed were developed using Medical Subject Headings (MeSH) and included the following MeSH terms as major topics: “anti-microbial”, “Pseudomonas”, “Acinetobacter”, and “Enterobacteriaceae” (Appendix B). Simultaneously, a similar set of search criteria was developed to evaluate ISI Web of Science for articles with the same topical coverage (Figure 1). These initial search criteria resulted in the identification of 12,643 records in PubMed and 77,862 records in ISI Web of Science (Figure 2). Importantly, it was noted that in both database searches, the total number of publications in this area increased linearly from the
period of 2010 – 2018 (Figure 2). From the PubMed database, the number of publications increased per annum from 901 publications in 2010 to 1,715 publications in 2018. In the ISI Web of Science search, the number of publications increased from 5,588 in 2010 to 9,866 publications in 2018. Notably, there was a decrease in the number of reported publications in 2019, which is hypothesized to be due to the delay in indexing of articles. We observed a nearly 2-fold increase in publication activity in the field of gram-negative antimicrobial pharmacotherapy during the 2010s.

Second, using the same search criteria above, citation analysis was conducted using the results from ISI Web of Science. Citation analysis differs from the number of total publications in that it identifies the number of times publications were cited in other peer-reviewed articles for a given period. This reflects the impact, or the extent of dissemination, of a group of peer-reviewed articles. The citation analysis quantified the total number of citations that articles published in a given year received (Figure 3). Articles that were published earlier in the decade accumulated more total citations than articles that were published later in the decade, since older articles have had more time to be discovered and cited. For example, articles published in 2010 were cited 183,032 times by 133,212 articles as compared to a fewer number of citations in 2019, in which 13,984 articles were cited by 11,540 articles. Also, articles published during this time exhibited an $h$-index of 139 in 2010 and 31 in 2019 (Figure 3). The $h$-index is a reflection of the number of publications, “$h$”, which have “$h$” number of citations; this is a useful metric for discriminating publications that are not yet cited and publications with a disproportionately high number of citations [10]. The average number of citations per item was 32.75 in 2010.
and 3 in 2019. The data reveals broad dissemination and the high impact of research in the field of gram-negative pharmacotherapy during the 2010s.

Third, an analysis of the total number of publications by drug class was also conducted (Figure 4). First, additional search terms for “penicillins”, “cephalosporins”, “aminoglycosides”, “fluoroquinolones”, “carbapenems”, and “polymyxins” was included in the original search criteria in PubMed (Appendix B). From these searches, the number of publications per drug class was quantified per annum over the course of the decade (Appendix C). The data revealed a steady publication rate for aminoglycosides, fluoroquinolones, and penicillins over the course of the decade. There were notable increases in the number of publications for cephalosporins from 2016 to 2018, carbapenems from 2014 to 2017, and polymyxins from 2014 to 2017. The polymyxins exhibited the most dramatic increase in publications, from 138 articles in 2015 to 202 articles in 2016. This increase likely reflected the increase in use of these antimicrobial agents in practice. A pie chart was compiled reflecting the percentage of publications from each drug class that composed the body of work during the 2010s (Figure 4). Approximately 25% of the articles were not categorized using the drug-class specific search criteria. These data reflect an increase in scholarly activity for cephalosporins, carbapenems, and polymyxins in the pharmacotherapy of gram-negative bacterial infections during the last half of the decade and relatively constant scholarly activity for penicillins, aminoglycosides, and fluoroquinolones during the 2010s.
Thematic analysis of major topics

Using the results of the literature review, the publications were narrowed down to review articles spanning January 1, 2010, to December 31, 2019, retrieved from PubMed to identify major publication themes. From this search, 407 review articles were identified and manually classified by publication themes via reading the title of the article and the abstract. From this, full-text publications of articles that encapsulated major publication “themes” were retrieved (Table 1).

The most common theme identified was the study of and management of infections caused by MDR bacteria. Throughout the 2010s, researchers focused on studying and reporting on inherently resistant GNRs such as *Pseudomonas aeruginosa* and *Acinetobacter baumanii* [11–15]. These organisms display resistance to antibiotics commonly used for community-acquired infections such as ceftriaxone and amoxicillin/clavulanic acid and can become resistant to other broad-spectrum antibiotics such as aminoglycosides, carbapenems, and polymyxins. During this time, many manuscripts were also published that described organisms which produce carbapenemases, such as *Klebsiella pneumoniae* carbapenemases (KPCs) and New Delhi metallo-beta-lactamase (NDM) [16–22]. Treating *Enterobacteriaceae* that produce carbapenemases can offer a clinical challenge as they can also be resistant to non-beta-lactam class antibiotics due to the co-existence of other resistance mechanisms [23].

The second most common theme was the management of pulmonary infection in patients with cystic fibrosis. Throughout the 2010s, several review articles evaluating the optimal method of antibiotic delivery in these patients were published. Inhaled antibiotics had been used before the 2010s, but the optimal use of this
method of antibiotic delivery was further evaluated [24–29]. Several oral and intravenous antibiotics were also investigated in inhaled formulations [30–34]. Additionally, the use of bronchoscopy-guided antimicrobial therapy was revisited throughout the decade [35–37]. Lastly, the management of *P. aeruginosa* specifically was the subject of many review articles, as it is one of the most common pathogens associated with acute and chronic cystic fibrosis infections [38–41].

The final theme identified during the review involved the use of antibiotics in animals and the subsequent development of resistance [42–45]. Antibiotics are commonly used as a growth promoter in livestock that are not infected. This practice leads to prolonged antibiotic exposure, which may promote the continued evolution of antimicrobial resistance. As of January 1, 2017, the FDA forbade the use of medically important antibiotics to promote growth in food animals [46]. This ruling likely contributed to an overall decrease in the sales of antimicrobials for use in animal feed from 2015, which was the year of peak use, but sales did increase between 2017 and 2018 [46]. This theme is likely to receive further attention in the coming decade.

An exceedingly important theme of the decade that was not captured by this evaluation was the increased focus on antimicrobial stewardship. The Center for Disease Control and Prevention (CDC) had a focus on antimicrobial stewardship prior to the 2010s with their “Get Smart” program, which was amplified in the following decade [47]. Throughout the 2010s, the CDC produced several evidence-based guidance documents, starting with the original CDC Core Elements of Hospital Antibiotic Stewardship Programs in 2014 [48–50]. These documents outlined evidence-based strategies for the creation and maintenance of impactful antimicrobial stewardship programs in the inpatient and outpatient setting. In
tandem, the Joint Commission created new requirements for healthcare organizations to create and maintain inpatient and outpatient stewardship programs in accordance with the CDC Core Elements in 2017 and 2020, respectively [51,52]. This renewed focus on antimicrobial stewardship by the federal government was accompanied by research into the topic. In particular, treating infections for decreasing durations was investigated with the prevailing conclusion being that shorter durations of therapy are as effective as longer durations of therapy [53,54].

**Review of new antibiotics approved under the GAIN Act**

Treatment of resistant *Enterobacteriaceae* poses a clinical challenge, and in the early 2010s, there were few effective antibiotics. For MDR GNRs that are resistant to carbapenems, treatment options included toxic antibiotics such as polymyxins and aminoglycosides or antibiotics with increased risk for mortality such as tigecycline. Unfortunately, there exist some strains of bacteria that are also resistant to these antibiotics. Before 2014, when the first QIDPs were approved under the GAIN Act, many researchers investigated the efficacy of combination antibiotic therapy. The specific combinations recommended depended on the species of bacteria and that strain’s specific susceptibility patterns. Possible regimens included combinations of polymyxins, carbapenems, aminoglycosides, tigecycline, fosfomycin, and the beta-lactamase inhibitor sulbactam [55–58]. As antibiotics with activity against carbapenem-resistant *Enterobacteriaceae* (CRE) were approved throughout the decade, combination therapy became necessary in fewer cases. In the latter half of the decade, there was less research done into combination therapy, and more investigation into repurposing older antibiotics to be used in combination therapy in the management of MDR bacteria, such as the use of
minocycline in combination with carbapenems or polymyxins in the treatment of *A. baumanii* [59].

The reason for less interest in combination therapy in the latter half of the decade could be due to several new antibiotics with activity against MDR GNRs being approved between 2014 and 2019 through the GAIN Act. A large focus of research during this time was how to most effectively utilize these new antibiotics.

1. **Ceftolozane/tazobactam**

Ceftolozane/tazobactam is a combination of the extended-spectrum cephalosporin, ceftolozane, and the beta-lactamase inhibitor, tazobactam. Ceftolozane is unique in its ability to overcome several defense mechanisms of *P. aeruginosa*. When compared to the third-generation cephalosporin ceftazidime, ceftolozane has stability in the presence of AmpC beta-lactamases, which are common in *P. aeruginosa*, has two-fold higher potency against penicillin-binding proteins, and is not a substrate for carbapenem-specific porins or efflux pumps found in *P. aeruginosa* [60–62]. Unfortunately, ceftolozane is susceptible to hydrolysis from some ESBLs, which is why it is packaged with tazobactam, to broaden ceftolozane’s activity [63]. Overall, ceftolozane/tazobactam’s main place in therapy is in the treatment of infections caused by MDR *P. aeruginosa* due to this cephalosporin combination’s unique resiliency against many of MDR *P. aeruginosa*’s common resistance mechanisms.
2. **Ceftazidime/avibactam**

Ceftazidime is a third-generation cephalosporin with broad-spectrum activity against gram-negative aerobes, including *P. aeruginosa*. Avibactam is a novel beta-lactamase inhibitor with activity against a variety of beta-lactamases including Ambler class A (TEM-1, CTX-M, SHV, KPC-2, and KPC-3), class C (AmpC), and certain class D (OXA-10 and OXA-48) [64–68]. Avibactam does not have activity against class B metallo beta-lactamases (e.g. NDM-1, VIM, and IMP) [66]. When compared to ceftolozane/tazobactam, ceftazidime/avibactam has greater activity against carbapenemase-producing CRE but has less activity against MDR *P. aeruginosa* isolates [69]. Overall, ceftazidime/avibactam's role in therapy is in the treatment of infections caused by CRE that produce specific beta-lactamases, such as KPC and OXA-48, that are effectively inhibited by avibactam.

3. **Delafloxacin**

Like the other fluoroquinolones, delafloxacin works by targeting DNA gyrase and topoisomerase IV to halt bacterial replication. For gram-negative bacteria, fluoroquinolones primarily target DNA gyrase, while for gram-positive bacteria, fluoroquinolones primarily target topoisomerase IV [70]. Delafloxacin is unique among fluoroquinolones in that it is equally potent against both DNA gyrase and topoisomerase IV, which may contribute to increased potency against resistant organisms [71]. While delafloxacin is effective against fluoroquinolone-resistant MRSA, it has limited efficacy against *P. aeruginosa*, *A. baumanii*, carbapenemase-producing *E. coli*, and carbapenemase-producing *K. pneumoniae* [72–74]. Overall,
like other currently available systemic fluoroquinolones, delafloxacin is of limited clinical use in the treatment of infections caused by MDR GNRs.

4. Meropenem/vaborbactam

As a carbapenem, meropenem is inherently resistant to degradation by penicillinases and cephalosporinases. Meropenem also has activity against inherently resistant GNRs such as *P. aeruginosa* and *A. baumanii* [75]. Vaborbactam is a carbapenemase-inhibitor with activity against Ambler class A beta-lactamas (KPC) and class C beta-lactamas (P99, MIR), but it does not exhibit activity against Ambler class B (NDM, VIM, IMP) or class D (OXA-48) beta-lactamas [76,77]. Overall, meropenem/vaborbactam’s role in therapy is similar to ceftazidime/avibactam in that the addition of vaborbactam restores the activity of meropenem against *Enterobacteriaceae* that produce KPCs. Unlike ceftazidime/avibactam, the addition of vaborbactam does not improve susceptibility in meropenem-resistant bacteria that produce OXA-48 beta-lactamas. Meropenem/vaborbactam is also of limited use in the treatment of MDR *P. aeruginosa* as the addition of vaborbactam does not affect carbapenem-specific porin channels.

5. Plazomicin

Plazomicin has exhibited activity against *Enterobacteriaceae* isolates with resistance against gentamicin, tobramycin, and amikacin [78]. This retained activity is due to plazomicin’s unique structure, which confers resistance to most aminoglycoside-modifying enzymes (AMEs) that cause aminoglycoside resistance [79]. Plazomicin does not have any unique protection against other mechanisms that confer bacterial resistance to aminoglycosides such as efflux pumps or target site
modification. Since most strains of MDR *P. aeruginosa* and *A. baumanii* often have additional mutations conferring aminoglycoside resistance along with producing aminoglycoside-modifying enzymes, plazomicin often has similar activity against these bacteria as other aminoglycosides [80]. Also, bacteria that produce carbapenemases such as NDM and OXA-type often have modified aminoglycoside target sites that confer resistance to all aminoglycosides, including plazomicin [81]. Despite this, Serio and colleagues showed 66% of NDM-producing *Enterobacteriaceae*, 89.6% of VIM-producing *Enterobacteriaceae*, and 100% of IMP-producing *Enterobacteriaceae* were susceptible to plazomicin [82]. For susceptible isolates, plazomicin is an option in the treatment of infections caused by metallo-beta-lactamases producing *Enterobacteriaceae*.

**6. Omadacycline**

Omadacycline is an aminomethylcycline in the tetracycline family of antibiotics with a unique structure that allows it to overcome many tetracycline-specific resistance mechanisms such as efflux pumps and target site protection [83]. Omadacycline does not exhibit activity against *Pseudomonas* spp., but it does inhibit some strains of *A. baumanii* [84]. Omadacycline does carry a warning for increased mortality based on the results of the OPTIC trial where more patients with community-acquired pneumonia treated with omadacycline (2.1%) than those treated with moxifloxacin (1.0%) died during the trial. The role of omadacycline in the treatment of MDR *Enterobacteriaceae* is currently unclear, but it could see use in the treatment of infections caused by bacteria producing carbapenemases such as KPCs, NDM, and OXA-48 or by susceptible *A. baumanii* or *Stenotrophomonas maltophilia* [85,86].
7. Eravacycline

Eravacycline is a fluorocycline in the tetracycline family of antibiotics that is similar to omadacycline in that its unique structure allows it to overcome common tetracycline resistance mechanisms such as ribosomal protection and efflux pumps [87]. Similar to omadacycline, eravacycline has no activity against *Pseudomonas* spp. but does inhibit some strains of *A. baumannii* and carbapenemase-producing *Enterobacteriaceae* [88]. While eravacycline did show noninferiority to ertapenem and meropenem in the treatment of complicated intra-abdominal infections, it was unable to achieve noninferiority compared to levofloxacin in the treatment of complicated urinary tract infections [87]. Overall, eravacycline’s role in the treatment of MDR *Enterobacteriaceae* is similar to omadacycline: it is an option to treat infections caused by bacteria producing carbapenemases or susceptible *A. baumannii*, but it may be particularly effective in the treatment of intra-abdominal infections.

8. Imipenem/cilastatin/relebactam

Imipenem, much like meropenem, is a carbapenem with a broad spectrum of activity against numerous bacteria including *P. aeruginosa* and *A. baumannii* [75]. Cilastatin is a dehydropeptidase-1 inhibitor that prevents renal metabolism of imipenem to allow for therapeutic concentrations of the antibiotic [89]. Relebactam is similar to avibactam in that it has activity against Ambler class A, C, and some D beta-lactamases [90,91]. While imipenem/cilastatin/relebactam has demonstrated activity against KPC-producing *Enterobacteriaceae*, the addition of relebactam did not restore imipenem’s activity against OXA-48 producing bacteria [92]. This is unlike ceftazidime/avibactam, which is active against OXA-48 producing bacteria [68]. The
role of imipenem/cilastatin/relebactam in clinical therapy is similar to meropenem/vaborbactam. The trio can be considered in the treatment of infections caused by *Enterobacteriaceae* that produce KPCs, but not those that produce OXA-48 or Ambler class B beta-lactamases.

9. **Cefiderocol**

Cefiderocol is unique in that it chelates with ferric iron, which allows it to be brought into GNRs via iron transport systems instead of through passive diffusion via porins like other beta-lactams [93,94]. This unique mechanism allows cefiderocol to overcome resistance conferred by decreased porin expression. While chelated with iron, cefiderocol is also resistant to hydrolysis by all beta-lactamases, including Ambler class B [95,96]. Cefiderocol has also shown *in-vitro* activity against MDR *Stenotrophomonas maltophilia*, MDR *A. baumannii*, and MDR *P. aeruginosa* [97]. Cefiderocol is approved for the treated of cUTI, but it has a labelled warning for increased mortality based on the results of the CREDIBLE-CR trial [98]. Overall, cefiderocol’s primary place in therapy is in the treatment of infections caused by MDR *S. maltophilia*, MDR *A. baumannii*, MDR *P. aeruginosa* and CRE that produce Ambler class B beta-lactamases.
CONCLUSION

The treatment of gram-negative bacterial infections has advanced considerably over the course of the last decade. In this current report, the field has evinced an increasing number of scholarly publications and dissemination as the 2010s progressed. This work identified publication themes of clinical practice that underwent rapid development during the 2010s. These themes included the management of infections caused by MDR GNRs and pulmonary infections in patients with cystic fibrosis. Also, the literature provided information on the declining scholarly interest in combination therapy for the treatment of MDR GNRs as newer antibiotics have been developed under the GAIN Act. Nine new antibiotics were covered in this literature review, most of which have niche roles in the treatment of MDR gram-negative bacterial infections. The 2010s was a decade of significant scholarship concerning the treatment of gram-negative bacterial infections, which portends further developments in this area of practice in the years to come.
ACKNOWLEDGEMENTS

The authors gratefully acknowledge Alison Konieczny for development of the literature search strategy in PubMed. Funding for this study was provided by the Ferris State University, College of Pharmacy to S.E.N.
References

1. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. New England Journal of Medicine. 2010; 362:1804–1813. Available at: http://www.nejm.org/doi/abs/10.1056/NEJMra0904124. Accessed 14 April 2020.

2. Miller SI. Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer Membrane Barrier by Host Innate Immune Molecules. mBio 2016; 7. Available at: https://mbio.asm.org/content/7/5/e01541-16. Accessed 9 June 2020.

3. Vaidya VK. Horizontal Transfer of Antimicrobial Resistance by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae. Journal of Laboratory Physicians 2011; 3:037–042.

4. Gomez JE, Kaufmann-Malaga BB, Wivagg CN, et al. Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment. eLife 2017; 6.

5. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. Journal of Bacteriology. 1996; 178:5853–5859.

6. Hidron AI, Edwards JR, Patel J, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infection Control & Hospital Epidemiology 2008; 29:996–1011. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18947320. Accessed 14 April 2020.

7. Darrow JJ, Kesselheim AS. Incentivizing Antibiotic Development: Why Isn’t the Generating Antibiotic Incentives Now (GAIN) Act Working? Available at: https://academic.oup.com/ofid/article-abstract/7/1/ofaa001/5716891. Accessed 14 April 2020.

8. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. International Journal of Infectious Diseases. 2011; 15.

9. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections. Clinical Infectious Diseases 2005; 40:1333–1341.

10. Hirsch JE. An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:16569–16572.
11. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Review of Anti-Infective Therapy. 2010; 8:71–93.

12. Briceño DF, Quinn JP, Villegas MV. Treatment options for multidrug-resistant nonfermenters. Expert Review of Anti-Infective Therapy. 2010; 8:303–315.

13. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options. International Journal of Antimicrobial Agents. 2012; 39:105–114.

14. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. International Journal of Antimicrobial Agents. 2015; 45:568–585.

15. Lupo A, Haenni M, Madec J-Y. Antimicrobial Resistance in Acinetobacter spp. and Pseudomonas spp. Microbiology Spectrum 2018; 6.

16. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. Available at: http://jac.oxfordjournals.

17. Arnold RS, Thom KA, Sharma S, Phillips M, Johnson JK, Morgan DJ. Emergence of Klebsiella pneumoniae Carbapenemase (KPC)-Producing Bacteria.

18. Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: Assessing their impact on organ transplantation. Current Opinion in Organ Transplantation. 2010; 15:676–682.

19. Rapp RP, Urban C. Klebsiella pneumoniae carbapenemases in enterobacteriaceae: History, evolution, and microbiology concerns. Pharmacotherapy 2012; 32:399–407.

20. Khan AU, Nordmann P. Spread of carbapenemase NDM-1 producers: The situation in India and what may be proposed. Scandinavian Journal of Infectious Diseases. 2012; 44:531–535.

21. Iredell J, Brown J, Tagg K. Antibiotic resistance in Enterobacteriaceae: Mechanisms and clinical implications. BMJ (Online). 2016; 352.

22. Iovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. Clinics in Laboratory Medicine. 2017; 37:303–315.
23. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends in Microbiology. 2011; 19:588–595.

24. Assael BM. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Expert Review of Anti-Infective Therapy. 2011; 9:967–973.

25. Lo D, VanDevanter DR, Flume P, Smyth A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: Continuous or intermittent? Respiratory Medicine 2011; 105.

26. Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database of Systematic Reviews 2012; 12.

27. Uttley L, Harman S, Cantrell A, et al. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. European Respiratory Review. 2013; 22:476–486.

28. Bos AC, Passé KM, Mouton JW, Janssens HM, Tiddens HAWM. The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug? Journal of Cystic Fibrosis. 2017; 16:13–23.

29. Uttley L, Tappenden P. Dry powder inhalers in cystic fibrosis: Same old drugs but different benefits? Current Opinion in Pulmonary Medicine. 2014; 20:607–612.

30. Parkins MD, Elborn JS. Aztreonam lysine: A novel inhalational antibiotic for cystic fibrosis. Expert Review of Respiratory Medicine. 2010; 4:435–444.

31. Parkins MD, Elborn JS. Tobramycin Inhalation Powder™: A novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Review of Respiratory Medicine. 2011; 5:609–622.

32. Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Review of Respiratory Medicine. 2015; 9:13–22.

33. Ehsan Z, Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiology 2015; 10:1901–1912.

34. Mckeage K. Tobramycin inhalation powder: A review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs. 2013; 73:1815–1827.
35. Jain K, Wainwright C, Smyth AR. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database of Systematic Reviews. 2018; 2018.

36. Jain K, Wainwright C, Smyth AR. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database of Systematic Reviews. 2013; 2013.

37. Jain K, Wainwright C, Smyth AR. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database of Systematic Reviews. 2016; 2016.

38. Hurley MN, Cámara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. European Respiratory Journal. 2012; 40:1014–1023.

39. Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric Pulmonology 2013; 48:525–537.

40. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews. 2014; 2014.

41. Langan KM, Kotsimbos T, Peleg AY. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Current Opinion in Infectious Diseases. 2015; 28:547–556.

42. Kempf I, Jouy E, Chauvin C. Colistin use and colistin resistance in bacteria from animals. International Journal of Antimicrobial Agents 2016; 48:598–606.

43. de Jong A, Stephan B, Silley P. Fluoroquinolone resistance of Escherichia coli and Salmonella from healthy livestock and poultry in the EU. Journal of Applied Microbiology. 2012; 112:239–245.

44. Moyaert H, de Jong A, Simjee S, Thomas V. Antimicrobial resistance monitoring projects for zoonotic and indicator bacteria of animal origin: Common aspects and differences between EASSA and EFSA. Veterinary Microbiology 2014; 171:279–283.

45. US Food and Drug Administration. Guidance for Industry #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with. 2013: 18. Available at: http://scholar.google.com/scholar?hl=en&btnG=Search&q=inGuidance+for+Industry+The+Judicious+Use+of+Medically+Important+Antimicrobi...
al+Drugs+in+Food-Producing+Animals#0%5Cnhttp://scholar.google.com/scholar?hl=en&btnG=Search&q=inGuidance+for+Indu. Accessed 25 May 2020.

46. FDA. Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. https://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUse rFeeActADUFA/UCM588085.pdf. 2017.

47. Demirjian A, Sanchez G v., Finkelstein JA, et al. CDC grand rounds: Getting smart about antibiotics. 2015: 871–873. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6432a3.htm. Accessed 27 May 2020.

48. Redfield RR, Khabbaz R. Core Elements of Hospital Antibiotic Stewardship Programs is a publication of The National Center for Emerging and Zoonotic Infectious Diseases within the Centers for Disease Control and Prevention. Centers for Disease Control and Prevention CORE ELEMENTS OF HOSPITAL ANTIBIOTIC STEWARDSHIP PROGRAMS. Available at: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.

49. Sanchez G v., Fleming-Dutra KE, Roberts RM, Hicks LA. Core Elements of Outpatient Antibiotic Stewardship. MMWR Recommendations and Reports 2016; 65:1–12. Available at: http://www.cdc.gov/mmwr/volumes/65/rr/rr6506a1.htm. Accessed 27 May 2020.

50. Department of Health U, Services H, for Disease Control C, Center for Zoonotic Infectious Diseases N, of Healthcare Quality Promotion D. CORE ELEMENTS OF HOSPITAL ANTIBIOTIC STEWARDSHIP PROGRAMS The Core Elements of Hospital Antibiotic Stewardship Programs. Available at: http://www.cdc.gov/getsmart/healthcare/.

51. APPROVED: New Antimicrobial Stewardship Standard. Joint Commission perspectives Joint Commission on Accreditation of Healthcare Organizations 2016; 36.

52. R3 Report Issue 23: Antimicrobial Stewardship in Ambulatory Health Care | The Joint Commission. Available at: https://www.jointcommission.org/en/standards/r3-report/r3-report-issue-23-antimicrobial-stewardship-in-ambulatory-health-care/. Accessed 27 May 2020.

53. Yahav D, Franceschini E, Koppel F, et al. Seven vs 14 Antibiotic Days for Bacteremia • CID. Clinical Infectious Diseases © 1091; 2019:1091–1099. Available at: https://academic.oup.com/cid/article-abstract/69/7/1091/5237874.
54. Spellberg B, Rice LB. Duration of antibiotic therapy: Shorter is better. Annals of Internal Medicine. 2019; 171:210–211.

55. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiology. 2011; 6:653–666.

56. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (When) might we still consider treating with carbapenems? Clinical Microbiology and Infection. 2011; 17:1135–1141.

57. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. Available at: https://academic.oup.com/jac/article-abstract/67/7/1607/729433.

58. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: An update. Expert Opinion on Pharmacotherapy. 2012; 13:2319–2336.

59. Greig SL, Scott LJ. Intravenous Minocycline: A Review in Acinetobacter Infections. Drugs 2016; 76:1467–1476.

60. Murano K, Yamanaka T, Toda A, et al. Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure. Bioorganic and Medicinal Chemistry 2008; 16:2261–2275.

61. Moya B, Dötsch A, Juan C, et al. β-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathogens 2009; 5.

62. Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2010; 54:3933–3937.

63. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus b-lactamase-producing Enterobacteriaceae. Available at: https://academic.oup.com/jac/article-abstract/65/9/1972/722603. Accessed 25 May 2020.

64. Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-b-lactam b-lactamase inhibitor. Available at: https://academic.oup.com/jac/article-abstract/54/2/410/767598. Accessed 25 May 2020.

65. Stachyra T, Péchereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-
lactamase inhibitor. Antimicrobial Agents and Chemotherapy 2010; 54:5132–5138.

66. Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2011; 55:390–394.

67. Ehmann DE, Jahić H, Ross PL, et al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. Journal of Biological Chemistry 2013; 288:27960–27971.

68. Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, et al. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. Diagnostic Microbiology and Infectious Disease 2015; 82:65–69.

69. Alatoom A, Elsayed H, Lawlor K, et al. Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. International Journal of Infectious Diseases 2017; 62:39–43.

70. Hooper DC. Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones. Clinical Infectious Diseases 2000; 31:S24–S28.

71. Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 2003; 47:3260–3269.

72. McCurdy S, Lawrence L, Quintas M, et al. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy 2017; 61.

73. Pfaller MA, Sader HS, Rhomberg PR, Flamm RK. In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrobial Agents and Chemotherapy 2017; 61.

74. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms. Antimicrobial Agents and Chemotherapy 2004; 48:2771–2777.
75. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagnostic Microbiology and Infectious Disease 2014; 78:443–448.

76. Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. Journal of Medicinal Chemistry 2015; 58:3682–3692.

77. Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2017; 61.

78. Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. Available at: http://www.ncbi.nlm.nih.gov/blast/. Accessed 25 May 2020.

79. Aggen JB, Armstrong ES, Goldblum AA, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrobial Agents and Chemotherapy 2010; 54:4636–4642.

80. Armstrong ES, Miller GH. Combating evolution with intelligent design: The neoglycoside ACHN-490. Current Opinion in Microbiology. 2010; 13:565–573.

81. Wachino JI, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: An update. Drug Resistance Updates 2012; 15:133–148.

82. Serio AW, Keepers T, Krause KM. Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae.

83. Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrobial Agents and Chemotherapy 2014; 58:1127–1135.

84. Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS. Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in mainland China, Hong Kong, and Taiwan: Results from the SENTRY antimicrobial surveillance Program (2013 to 2016). Antimicrobial Agents and Chemotherapy. 2019; 63.
85. Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. New England Journal of Medicine 2019; 380:517–527.

86. Villano S, Steenbergen J, Loh E. Omadacycline: Development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiology. 2016; 11:1421–1434.

87. Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial a randomized clinical trial. JAMA Surgery 2017; 152:224–232.

88. Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrobial Agents and Chemotherapy 2013; 57:5548–5558.

89. Kahan FM, Kropp H, Sundeloef JG, Birnbaum J. Thienamycin: development of imipenem-cilastatin. Journal of Antimicrobial Chemotherapy 1983; 12:1–35. Available at: https://doi.org/10.1093/jac/12.suppl_D.1.

90. Blizzard TA, Chen H, Kim S, et al. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®. Bioorganic and Medicinal Chemistry Letters 2014; 24:780–785.

91. Shlaes DM. New β-lactam-β-lactamase inhibitor combinations in clinical development. Annals of the New York Academy of Sciences 2013; 1277:105–114.

92. Canver MC, Satlin MJ, Westblade LF, et al. Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 2019; 63.

93. Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 2016; 60:7396–7401.

94. Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrobial Agents and Chemotherapy 2018; 62.

95. Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae
clinical isolates, including carbapenem-resistant strains. Antimicrobial Agents and Chemotherapy 2016; 60:729–734.

96. Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrobial Agents and Chemotherapy 2016; 60:4384–4386.

97. Delgado-Valverde M, del Carmen Conejo M, Serrano L, Fernández-Cuenca F, Lvaro Pascual A. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Available at: https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkaa117/5819169.

98. Bassetti M, Ariyasu M, Binkowitz B, et al. Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant gram-negative pathogens – the international, multicenter, randomized, open-label, phase 3 credible-cr study. Infection and Drug Resistance 2019; 12:3607–3623.

99. Adeolu M, Alnajar S, Naushad S, Gupta RS. Genome-based phylogeny and taxonomy of the ‘Enterobacterales’: Proposal for enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. International Journal of Systematic and Evolutionary Microbiology 2016; 66:5575–5599.
Figure 1 Literature search strategy and results.

Build search criteria for the literature search.

- Anti-microbial
- Enterobacteriaceae
- Pseudomonas
- Acinetobacter

Limit search period from January 1, 2010, to December 31, 2019.

Search Pubmed database using search criteria as major medical subject headings (MeSH).

Records identified using MeSH and time period criteria (n = 12,643 articles).

Search ISI Web of Science literature database using search criteria.

Records identified using keyword and time criteria (n = 77,862 articles).

Records further screened based on additional drug class search terms. (n = 9,453 articles).

Citation analysis carried out for the total number of citations, citing articles, h-index, and average citations per item.

Review articles manually searched and tallied to identify major thematic groupings for literature review (n = 406 articles).
Figure 2 Total number of publications about gram-negative antimicrobials published from 2010 to 2019. (A) The total number of publications indexed in PubMed. (B) The total number of publications indexed in ISI Web of Science.
Figure 3 Citation analysis of publications indexed in Web of Science from 2010 – 2019. (A) Total citation count and number of citing articles and (B) average h-index and average citations per item.
Figure 4 Percent contribution of total publications per drug class from 2010 – 2019.

Publications By Drug Class 2010-2019

- Aminoglycosides: 25%
- Cephalosporins: 13%
- Polymyxins: 13%
- Carabapenems: 11%
- Fluroquinolones: 7%
- Penicillins: 10%
- Uncategorized: 21%

Downloaded from https://academic.oup.com/ofid/article-abstract/doi/10.1093/ofid/ofaa276/5867191 by guest on 07 July 2020
Table 1 Evaluation of literature topics via thematic analysis.

| Topic                                           | Number |
|-------------------------------------------------|--------|
| Pharmacotherapy of MDR bacteria                 | 95     |
| Generalized MDR gram-negative pathogens (KPC, NDM, OXA-48, VIM, IMP) | 58     |
| *Pseudomonas*                                   | 53     |
| *Acinetobacter*                                 | 45     |
| Cystic fibrosis management                      | 32     |
| Resistance Mechanisms                           | 24     |
| Specific Antimicrobial Agents                   | 22     |
| Specific Diseases                               | 20     |
| Animal Topics                                   | 16     |

MDR = multidrug-resistant, KPC = *Klebsiella pneumoniae* carbapenemase-producing bacteria, NDM = New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae, OXA-48 = oxacillinase/carbapenemase-producing *Klebsiella pneumoniae*, VIM = Verona Integron-Mediated Metallo-β-lactamase-producing GNRs. The table includes the evaluation of major themes of 407 review articles. As some review articles did not fit within any of these major themes, the numbers in the table will not add up to 407.